(Reuters) – Gilead Sciences Inc said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with COVID-19.
The company said it no longer believes that developing a multiple day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.
The decision to stop the study is not due to efficacy or safety concerns, Gilead said.
(Reporting by Dania Nadeem in Bengaluru; Editing by Anil D’Silva)
